Janus Henderson Group PLC Acquires 43,405 Shares of PROCEPT BioRobotics Corporation $PRCT

Janus Henderson Group PLC increased its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 12.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 384,246 shares of the company’s stock after purchasing an additional 43,405 shares during the period. Janus Henderson Group PLC owned approximately 0.68% of PROCEPT BioRobotics worth $9,610,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in shares of PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after purchasing an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of PROCEPT BioRobotics by 9.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock worth $8,923,000 after buying an additional 13,767 shares during the period. Intech Investment Management LLC boosted its stake in PROCEPT BioRobotics by 54.4% in the 1st quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock valued at $1,654,000 after buying an additional 10,002 shares in the last quarter. Prudential Financial Inc. grew its position in PROCEPT BioRobotics by 100.4% in the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after acquiring an additional 3,415 shares during the period. Finally, State Street Corp grew its position in PROCEPT BioRobotics by 6.9% in the second quarter. State Street Corp now owns 1,269,110 shares of the company’s stock valued at $73,101,000 after acquiring an additional 81,849 shares during the period. Institutional investors own 89.46% of the company’s stock.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue rose 19.3% year over year to $94.5 million, exceeding analysts’ $92.77 million estimate. The result suggests continued demand for PROCEPT’s urology-focused robotic systems despite broader concerns about customer inventory. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management forecast fiscal 2026 revenue of $390 million to $410 million, a range that broadly brackets the $397.2 million consensus estimate and may have eased concerns about a sharp near-term slowdown.
• Neutral Sentiment: The company reported an adjusted loss of $0.47 per share, narrowly missing the $0.46 consensus estimate and worsening from a $0.35 loss in the year-ago quarter. PROCEPT remains unprofitable, with analysts expecting a full-year loss. PROCEPT BioRobotics Reports Q2 Loss, Beats Revenue Estimates
• Negative Sentiment: Wells Fargo downgraded PROCEPT from “overweight” to “equal weight” and set a $19 price target, signaling limited upside at recent trading levels. Wells Fargo downgrade report
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. The allegations include material misstatements about product demand, excess customer inventory, and late-quarter bulk discounts that may have overstated recurring-revenue trends. Investors seeking lead-plaintiff status generally face a September 22, 2026 deadline. Levi & Korsinsky PROCEPT class action alert

Analyst Ratings Changes

A number of research analysts have issued reports on PRCT shares. Leerink Partners cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $31.00 to $29.00 in a report on Thursday, June 11th. Wells Fargo & Company cut shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 target price for the company. in a research report on Wednesday. Jefferies Financial Group reiterated a “hold” rating and set a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday. Piper Sandler reduced their price target on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Wall Street Zen raised shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Hold” and a consensus target price of $28.00.

PROCEPT BioRobotics Price Performance

Shares of PRCT stock opened at $19.34 on Thursday. The stock’s fifty day moving average is $21.85 and its 200-day moving average is $24.89. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73. The stock has a market capitalization of $1.10 billion, a PE ratio of -9.97 and a beta of 0.89. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $47.97.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The business had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.10%. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) earnings per share. Equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.